Molecular Staging Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$35.2M
Molecular Staging General Information
Description
Developer of technologies for the detection and measurement of proteins and nucleic acids. The company provides technologies for proteomics, genomics, pharmacogenomics and diagnostics applications. The company develops Whole Genome Amplification (WGA) technology which is designed to eliminate limitations created by scarce quantities of DNA samples.
Contact Information
Website
www.molecularstaging.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Acquirer
Primary Office
- 300 George Street
- New Haven, CT 06511
- United States
+1 (203) 000-0000
Molecular Staging Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 27-Sep-2004 | $35.2M | 000.00 | 000.00 | Completed | Generating Revenue |
| 5. Grant | 08-Oct-2001 | 00.00 | 000.00 | Completed | ||
| 4. Later Stage VC (Series D) | 000.00 | 000.00 | 00000 | Completed | Generating Revenue | |
| 3. Later Stage VC (Series C) | 06-Nov-2000 | 0000 | 000.00 | 00000 | Completed | Generating Revenue |
| 2. Early Stage VC (Series B) | 04-Feb-1999 | $5.17M | $18.7M | 00000 | Completed | Product Development |
| 1. Early Stage VC (Series A) | 01-Jan-1998 | $13.5M | $13.5M | 000.00 | Completed | Product Development |
Molecular Staging Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00.00 | 00.000 | |
| Series C2 | 000,000 | 00.000000 | 000 | 000 | 00 | 000 | 0.000 | |
| Series C1 | 000,000 | 00.000000 | 000 | 000 | 00 | 000 | 0.000 | |
| Series B | 700,000 | $0.010000 | $7.38 | $7.38 | 1x | $7.38 | 3.4% | |
| Series A | 4,500,000 | $0.010000 | $0.24 | $3 | $3 | 1x | $3 | 21.87% |
Molecular Staging Patents
Molecular Staging Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1585833-A4 | Rolling circle amplification of rna | Active | 31-Dec-2002 | 00000000000 | 0 |
| EP-1585833-A2 | Rolling circle amplification of rna | Active | 31-Dec-2002 | 00000000000 | 0 |
| US-20040101510-A1 | Anticancer agents; antiarthritic agents; antiproliferative agents; measurement protein, calibration cell proliferation | Inactive | 26-Nov-2002 | 0000000000 | 0 |
| AU-2003293023-A8 | Chemokine parc suppresses specific cytokine production | Inactive | 26-Nov-2002 | 0000000000 | |
| AU-2003293023-A1 | Chemokine parc suppresses specific cytokine production | Inactive | 26-Nov-2002 | A61K38/195 |
Molecular Staging Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| CHL Medical Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| CIBC Capital Partners | Investment Bank | Minority | 000 0000 | 000000 0 | |
| Cooper Hill Partners | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Domain Associates | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Investor | PE/Buyout | Minority | 000 0000 | 000000 0 |